LABB.MX
Genomma Lab Internacional, S.A.B. de C.V. [LABB.MX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LABB.MX Stock Summary
Top 10 Correlated ETFs
LABB.MX
Top 10 Correlated Stocks
LABB.MX
In the News
LABB.MX Financial details
Company Rating
Strong Buy
Market Cap
14.56B
Income
1.45B
Revenue
17.07B
Book val./share
-
Cash/share
-
Dividend
0.59
Dividend %
4.17%
Employees
1.78K
Optionable
No
Shortable
Yes
Earnings
24 Apr 2024
P/E
9.37
Forward P/E
-
PEG
6.09
P/S
0.8
P/B
1.28
P/C
-
P/FCF
8.59
Quick Ratio
0.26
Current Ratio
1.75
Debt / Equity
0.6
LT Debt / Equity
0.39
-
-
EPS (TTM)
1.5
EPS next Y
-
EPS next Q
-
EPS this Y
7.69%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
5.33%
Revenue last 5Y
7.36%
Revenue Q/Q
0.52%
EPS Q/Q
-11.63%
-
-
-
-
SMA20
4.09%
SMA50
6.08%
SMA100
5.71%
Inst Own
0%
Inst Trans
0%
ROA
7%
ROE
14%
ROC
0.22%
Gross Margin
60%
Oper. Margin
20%
Profit Margin
9%
Payout
27%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
12.39-15.94
52W High
-2.8%
52W Low
+21.5%
RSI
46.21
Rel Volume
0.84
Avg Volume
3.57M
Volume
2.98M
Perf Week
-7.31%
Perf Month
4.67%
Perf Quarter
12.07%
Perf Half Y
8.81%
-
-
-
-
Beta
0.466
-
-
Volatility
0.47%, 0.61%
Prev Close
3.4%
Price
14.58
Change
2.03%
LABB.MX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 11.52 | 12.55 | 13.71 | 15.37 | 16.93 | |
| Net income per share | 1.08 | 0.75 | 1.39 | 1.3 | 1.4 | |
| Operating cash flow per share | 1.53 | 0.99 | 1.69 | 1.46 | 2.07 | |
| Free cash flow per share | 0.05 | 0.13 | 1.69 | 1.25 | 2.05 | |
| Cash per share | 1.36 | 0.89 | 2.02 | 1.21 | 1.51 | |
| Book value per share | 7.26 | 7.87 | 9.52 | 10 | 10.22 | |
| Tangible book value per share | 2.44 | 3.02 | 4.67 | 4.87 | 5.04 | |
| Share holders equity per share | 7.26 | 7.87 | 9.52 | 10 | 10.22 | |
| Interest debt per share | 6.28 | 6.62 | 6.86 | 6.36 | 7.01 | |
| Market cap | 11.95B | 18.82B | 19.06B | 21.64B | 16.76B | |
| Enterprise value | 16.43B | 24.02B | 23.5B | 26.38B | 21.7B | |
| P/E ratio | 10.77 | 24.62 | 13.58 | 16.55 | 12.06 | |
| Price to sales ratio | 1.01 | 1.48 | 1.37 | 1.4 | 1 | |
| POCF ratio | 7.65 | 18.69 | 11.12 | 14.74 | 8.15 | |
| PFCF ratio | 238 | 144.43 | 11.17 | 17.15 | 8.23 | |
| P/B Ratio | 1.61 | 2.36 | 1.98 | 2.15 | 1.65 | |
| PTB ratio | 1.61 | 2.36 | 1.98 | 2.15 | 1.65 | |
| EV to sales | 1.39 | 1.89 | 1.69 | 1.7 | 1.29 | |
| Enterprise value over EBITDA | 6.31 | 9.88 | 7.74 | 8.31 | 6.38 | |
| EV to operating cash flow | 10.51 | 23.86 | 13.7 | 17.97 | 10.56 | |
| EV to free cash flow | 327.29 | 184.33 | 13.77 | 20.91 | 10.66 | |
| Earnings yield | 0.09 | 0.04 | 0.07 | 0.06 | 0.08 | |
| Free cash flow yield | 0 | 0.01 | 0.09 | 0.06 | 0.12 | |
| Debt to equity | 0.79 | 0.76 | 0.67 | 0.59 | 0.63 | |
| Debt to assets | 0.32 | 0.32 | 0.29 | 0.28 | 0.3 | |
| Net debt to EBITDA | 1.72 | 2.14 | 1.46 | 1.49 | 1.45 | |
| Current ratio | 2.01 | 1.73 | 1.82 | 1.75 | 1.21 | |
| Interest coverage | 4.15 | 3.84 | 6 | 6.86 | 6.17 | |
| Income quality | 1.41 | 1.32 | 1.17 | 1.12 | 1.48 | |
| Dividend Yield | 0 | 0 | 0 | 0.02 | 0.05 | |
| Payout ratio | 0 | 0 | 0 | 0.3 | 0.56 | |
| Sales general and administrative to revenue | 0.47 | 0.46 | 0.41 | 0.42 | 0.41 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.27 | 0.26 | 0.22 | 0.24 | 0.24 | |
| Capex to operating cash flow | -0.97 | -0.87 | 0 | -0.14 | -0.01 | |
| Capex to revenue | -0.13 | -0.07 | 0 | -0.01 | 0 | |
| Capex to depreciation | -18.63 | -6.16 | -0.05 | -1.21 | -0.09 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 13.3 | 11.56 | 17.24 | 17.09 | 17.94 | |
| ROIC | 0.11 | 0.08 | 0.11 | 0.11 | 0.12 | |
| Return on tangible assets | 0.08 | 0.05 | 0.08 | 0.08 | 0.08 | |
| Graham Net | -8.21 | -9.31 | -9.32 | -9.08 | -8.82 | |
| Working capital | 4.51B | 4.14B | 5.42B | 4.95B | 1.96B | |
| Tangible asset value | 2.49B | 3.06B | 4.73B | 4.9B | 5B | |
| Net current asset value | -1.65B | -1.46B | -460.96M | 50.32M | -141.79M | |
| Invested capital | 0.79 | 0.76 | 0.67 | 0.59 | 0.63 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 1.44B | 1.83B | 1.76B | 1.54B | 1.62B | |
| Average inventory | 1.48B | 1.8B | 1.98B | 2.12B | 2.3B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 160.72 | 148.78 | 113.66 | 88.7 | 98.18 | |
| Days of inventory on hand | 153.71 | 150.89 | 141.38 | 135.67 | 131.44 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 2.27 | 2.45 | 3.21 | 4.11 | 3.72 | |
| Inventory turnover | 2.37 | 2.42 | 2.58 | 2.69 | 2.78 | |
| ROE | 0.15 | 0.1 | 0.15 | 0.13 | 0.14 | |
| Capex per share | -1.48 | -0.87 | -0.01 | -0.21 | -0.02 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.51 | 4.28 | 4.33 | 4.53 | 0 | |
| Net income per share | 0.41 | 0.32 | 0.37 | 0.43 | 0 | |
| Operating cash flow per share | 0.42 | 0.35 | 0.33 | 0.46 | 0 | |
| Free cash flow per share | 0.32 | 0.35 | 0.24 | 0.42 | 0 | |
| Cash per share | 1.13 | 1.55 | 2.29 | 1.42 | 0 | |
| Book value per share | 11.32 | 10.53 | 10.76 | 10.84 | 0 | |
| Tangible book value per share | 6.11 | 5.19 | 5.6 | 5.54 | 0 | |
| Share holders equity per share | 11.32 | 10.53 | 10.76 | 10.84 | 0 | |
| Interest debt per share | 5.44 | 6.85 | 6.54 | 6.73 | 0 | |
| Market cap | 13.41B | 16.27B | 14B | 12.71B | 0 | |
| Enterprise value | 17.42B | 21.22B | 18.87B | 17.62B | 2.35B | |
| P/E ratio | 8.39 | 13.22 | 9.77 | 7.61 | 0 | |
| Price to sales ratio | 3.08 | 3.94 | 3.35 | 2.91 | 0 | |
| POCF ratio | 33.05 | 48.19 | 44.01 | 28.39 | 0 | |
| PFCF ratio | 43.43 | 48.19 | 59.58 | 31.61 | 0 | |
| P/B Ratio | 1.23 | 1.6 | 1.35 | 1.22 | 0 | |
| PTB ratio | 1.23 | 1.6 | 1.35 | 1.22 | 0 | |
| EV to sales | 4.01 | 5.13 | 4.52 | 4.03 | 0.53 | |
| Enterprise value over EBITDA | 18.68 | 26.15 | 24.65 | 21.03 | 2.56 | |
| EV to operating cash flow | 42.95 | 62.84 | 59.34 | 39.35 | 3.55 | |
| EV to free cash flow | 56.43 | 62.84 | 80.34 | 43.81 | 3.84 | |
| Earnings yield | 0.03 | 0.02 | 0.03 | 0.03 | 0 | |
| Free cash flow yield | 0.02 | 0.02 | 0.02 | 0.03 | 0 | |
| Debt to equity | 0.47 | 0.63 | 0.59 | 0.6 | 0.6 | |
| Debt to assets | 0.23 | 0.3 | 0.28 | 0.29 | 0.29 | |
| Net debt to EBITDA | 4.3 | 6.1 | 6.37 | 5.85 | 2.56 | |
| Current ratio | 1.24 | 1.21 | 1.21 | 1.65 | 1.75 | |
| Interest coverage | 6.28 | 4.75 | 4.42 | 3.93 | 4.26 | |
| Income quality | 1.02 | 1.78 | 0.89 | 1.07 | 1.79 | |
| Dividend Yield | 0 | 0 | 0 | 0.02 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0.47 | 0.52 | |
| Sales general and administrative to revenue | 0.42 | 0.4 | 0.42 | 0.41 | 0.41 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.23 | 0.24 | 0.23 | 0.24 | 0.23 | |
| Capex to operating cash flow | -0.24 | 0 | -0.26 | -0.1 | -0.08 | |
| Capex to revenue | -0.02 | 0 | -0.02 | -0.01 | -0.01 | |
| Capex to depreciation | -1.68 | 0 | -1.21 | -0.75 | -0.84 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 10.27 | 8.69 | 9.48 | 10.28 | 0 | |
| ROIC | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | |
| Return on tangible assets | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | |
| Graham Net | -8.69 | -9.08 | -8.38 | -9.06 | 0 | |
| Working capital | 2.27B | 1.96B | 1.99B | 4.54B | 5.13B | |
| Tangible asset value | 5.89B | 5B | 5.4B | 5.34B | 5.51B | |
| Net current asset value | 678.49M | -141.79M | 25.2M | 306.61M | 484.48M | |
| Invested capital | 0.47 | 0.63 | 0.59 | 0.6 | 0.6 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 2.04B | 1.94B | 1.69B | 1.74B | 1.93B | |
| Average inventory | 2.69B | 2.63B | 2.37B | 2.28B | 2.26B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 113.44 | 90.49 | 88.93 | 99.02 | 108.48 | |
| Days of inventory on hand | 154.67 | 121.16 | 130.34 | 116.88 | 125.78 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.79 | 0.99 | 1.01 | 0.91 | 0.83 | |
| Inventory turnover | 0.58 | 0.74 | 0.69 | 0.77 | 0.72 | |
| ROE | 0.04 | 0.03 | 0.03 | 0.04 | 0.03 | |
| Capex per share | -0.1 | 0 | -0.09 | -0.05 | 0 |
LABB.MX Frequently Asked Questions
What is Genomma Lab Internacional, S.A.B. de C.V. stock symbol ?
Genomma Lab Internacional, S.A.B. de C.V. is a MX stock , located in Mexico city of Df and trading under the symbol LABB.MX
What is Genomma Lab Internacional, S.A.B. de C.V. stock quote today ?
Genomma Lab Internacional, S.A.B. de C.V. stock price is $14.58 today.
Is Genomma Lab Internacional, S.A.B. de C.V. stock public?
Yes, Genomma Lab Internacional, S.A.B. de C.V. is a publicly traded company.
Company Profile
- Volume Average 3.57M
- Market Capitalization 14.56B
- Employee 1.78K
- CEO Mr. Juan Marco Sparvieri
- Headquarters Mexico City,DF,MX
- IPO Date 2008-06-18
-
Website
https://www.genommalab.com 
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, engages in the development, marketing, and sale of over-the-counter pharmaceutical and personal care products in Mexico and internationally. It provides skin care, health and wellness, hair care, pain relief, cough and cold, gastro, sexual health, antiperspirant deodorant, hand sanitizer, isotonic deink, and razor products, as well as analgesics, antifungals, and hemorrhoids. The company offers its products under the Cicatricure, Asepxia, Teatrical, Goicoechea, Sistema GB, Medicasp, Tío Nacho, Vanart, Novamil, Ultra Bengue, X-Ray, Tafirol, Alliviax, Bufferin, Next, XL-3, Genoprazol, QG5, Kaopectate, Proctan, Nikzon, Unesia, Silka Medic, lagicam, Suerox, Groomen, DiabetTX, and other brands. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.
